Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 12-Month Low – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $6.76 and last traded at $6.81, with a volume of 1225637 shares changing hands. The stock had previously closed at $6.95.

Wall Street Analyst Weigh In

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. According to MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Stock Performance

The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The stock’s 50-day moving average price is $7.64 and its 200 day moving average price is $7.47. The company has a market cap of $26.72 billion, a P/E ratio of -18.81 and a beta of 1.08.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The company had revenue of $12 billion for the quarter. As a group, research analysts expect that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.